<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00315406</url>
  </required_header>
  <id_info>
    <org_study_id>VCRC5504</org_study_id>
    <secondary_id>U54AR057319</secondary_id>
    <nct_id>NCT00315406</nct_id>
  </id_info>
  <brief_title>Determining Disease Activity Biomarkers in Individuals With Polyarteritis Nodosa</brief_title>
  <official_title>Longitudinal Protocol of Polyarteritis Nodosa</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Office of Rare Diseases (ORD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rare Diseases Clinical Research Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Polyarteritis nodosa (PAN) is a rare immune system disorder that causes swelling and damage
      to small- and medium-sized blood vessels in the body. In order to properly treat this
      disease, it is critical that the level of disease activity can be determined over the course
      of the disease. The purpose of this study is to determine new biological markers, or
      biomarkers, that may be used to assess the severity of disease in people with PAN.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PAN, also known as systemic necrotic vasculitis, was the first recognized form of primary
      systemic vasculitis. PAN causes the inflammation of small- to medium-sized blood vessels,
      especially those supplying the nerves, skin, kidneys, gastrointestinal tract, heart, eye, and
      genitals. Unlike another form of vasculitis called microscopic polyangiitis, PAN does not
      usually cause glomerulonephritis, a type of kidney disease, or vasculitis in the very
      smallest blood vessels (arterioles, capillaries, and venules). There are no radiographic or
      serologic tests that can reliably measure disease activity in PAN. Currently, clinicians must
      rely on patients' symptoms, signs, laboratory tests, and imaging to guide treatment
      decisions, but such data are rarely consistently reliable in determining PAN disease
      activity. This study will use new scientific methods to discover new biomarkers that can be
      used to monitor disease activity in PAN patients. These biomarkers may be used to help direct
      clinical care for PAN patients and assist in future drug development.

      Study visits will occur monthly for the first year, then every 3 months thereafter for the
      remainder of the study. Blood and urine collection will occur at every visit. A physical exam
      and medical and medication history will occur every 3 months; also, participants will be
      asked to complete several questionnaires to assess disease activity, health status, and
      tobacco, alcohol, and drug use. Participants may have additional study visits if a disease
      flare or disease-related complications occur during the study.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 2006</start_date>
  <completion_date type="Anticipated">April 2019</completion_date>
  <primary_completion_date type="Anticipated">April 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Discover biomarkers in PAN capable of measuring disease activity and response to treatment.</measure>
    <time_frame>Study completion</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measure the predictive value of biomarkers for clinical outcome in PAN.</measure>
    <time_frame>Study completion.</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Polyarteritis Nodosa</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood (serum and plasma), urine, and DNA
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Individuals with polyarteritis nodosa. Enrollment will be sequential and participants will
        have disease in various stages and of different duration.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Parent or guardian willing to provide informed consent, if applicable

          -  Diagnosis of vasculitis

          -  Diagnosis of PAN, meeting at least 1 major criterion and 1 minor criterion OR 2 major
             criteria of the following adapted American College of Rheumatology (ACR) criteria that
             fall under the diagnosis of PAN and that are not explained by other causes:

        MAJOR CRITERIA

          1. Arteriographic abnormality

          2. Presence of granulocyte or mixed leukocyte infiltrate in an arterial wall on biopsy

          3. Mononeuropathy or polyneuropathy

        MINOR CRITERIA

          1. Weight loss of more than 4 kg (8.8 lbs)

          2. Livedo reticularis, cutaneous ulcerations, or skin nodules

          3. Testicular pain or tenderness

          4. Myalgias

          5. Diastolic blood pressure greater than 90 mm Hg

          6. Elevated blood urea nitrogen (BUN) or serum creatinine levels

          7. Ischemic abdominal pain

        Exclusion Criteria:

          -  Microscopic polyangiitis

          -  Granulomatosis with polyangiitis(Wegener's)

          -  Eosinophilic granulomatosis with polyangiitis (Churg-Strauss)

          -  Takayasu's arteritis

          -  Giant cell arteritis

          -  Cogan's syndrome

          -  Behcet's disease

          -  Sarcoidosis

          -  Kawasaki disease

          -  Cryoglobulinemic vasculitis

          -  Systemic lupus erythematosus

          -  Rheumatoid arthritis

          -  Mixed connective tissue disease or any overlap autoimmune syndrome

          -  Presence of antiproteinase 3 or antimyeloperoxidase antineutrophil cytoplasmic
             antibodies (ANCA)

          -  Glomeronephritis

          -  Alveolar hemorrhage

          -  Hepatitis B, hepatitis C, or HIV infection

          -  Any other infectious form of medium vessel vasculitis

          -  Isolated cutaneous PAN
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter A. Merkel, MD, MPH</last_name>
    <role>Study Chair</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Boston University School of Medicine</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Naomi Amudala, NP</last_name>
      <phone>617-414-2512</phone>
      <email>namudala@bu.edu</email>
    </contact>
    <investigator>
      <last_name>Paul A. Monach, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic College of Medicine</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jane Jaquith</last_name>
      <email>jaquith.jane@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Steven R. Ytterberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Kisela</last_name>
      <email>kiselae@ccf.org</email>
    </contact>
    <investigator>
      <last_name>Carol A. Langford, MD, MHS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>B.Minal Hatwar</last_name>
      <email>Bhagyavati.Hatwar@uphs.upenn.edu</email>
    </contact>
    <investigator>
      <last_name>Peter Merkel, MD, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15260</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurie Hope</last_name>
      <email>hopelk@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>Larry Moreland, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica gonzalez</last_name>
      <email>jessica.gonzalez@hsc.utah.edu</email>
    </contact>
    <investigator>
      <last_name>Curry Koening, MD, MHS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Joseph's Healthcare</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandra Messier</last_name>
      <phone>905-522-1155</phone>
      <phone_ext>35873</phone_ext>
      <email>smessier@stjoes.ca</email>
    </contact>
    <investigator>
      <last_name>Nader A. Khalidi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5T 3L9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Judy Vendramini</last_name>
      <email>judy.vendramini@sinaihealthsystem.ca</email>
    </contact>
    <investigator>
      <last_name>Simon Carette, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://rarediseasesnetwork.org/vcrc/</url>
    <description>Vasculitis Clinical Research Consortium</description>
  </link>
  <link>
    <url>http://rarediseasesnetwork.epi.usf.edu/</url>
    <description>Rare Diseases Clinical Research Network</description>
  </link>
  <reference>
    <citation>Bonsib SM. Polyarteritis nodosa. Semin Diagn Pathol. 2001 Feb;18(1):14-23. Review.</citation>
    <PMID>11296989</PMID>
  </reference>
  <reference>
    <citation>Said G, Lacroix C. Primary and secondary vasculitic neuropathy. J Neurol. 2005 Jun;252(6):633-41. Epub 2005 Apr 5. Review.</citation>
    <PMID>15806339</PMID>
  </reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 14, 2006</study_first_submitted>
  <study_first_submitted_qc>April 14, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 18, 2006</study_first_posted>
  <last_update_submitted>April 23, 2018</last_update_submitted>
  <last_update_submitted_qc>April 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pennsylvania</investigator_affiliation>
    <investigator_full_name>Peter Merkel</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>PAN</keyword>
  <keyword>Periarteritis Nodosa</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polyarteritis Nodosa</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

